DCP
IONS icon

Davern Capital Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Davern Capital Partners’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.3M Buy
798,709
+411,806
+106% +$31M 10.8% 4
2026
Q1 		$29.1M Buy
386,903
+148,426
+62% +$11.7M 7.97% 4
2025
Q4 		$18.9M Buy
+238,477
New +$18M 6.1% 8

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Davern Capital Partners's IONS Position: Q2 2026 in Review

Davern Capital Partners increased its Ionis Pharmaceuticals (IONS) stake by 106% in Q2 2026, buying an estimated $31M and bringing the position to 798,709 shares worth $63.3M. The position accounts for 10.8% of the portfolio, ranked #4.

Davern Capital Partners first reported a position in IONS in Q4 2025 and has held it in 3 quarters since. 513 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Davern Capital Partners held 798,709 shares of Ionis Pharmaceuticals worth $63.3M as of Q2 2026.
  • Davern Capital Partners bought 411,806 Ionis Pharmaceuticals shares in Q2 2026, an estimated $31M.
  • Ionis Pharmaceuticals made up 10.8% of Davern Capital Partners's portfolio in Q2 2026, its #4 holding.
  • Davern Capital Partners first reported a position in Ionis Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 513 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Davern Capital Partners's 13F filing for Q2 2026, filed 13 Aug 2026.